Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.

Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol. 2021 Feb 18;: Authors: Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M PMID: 33604778 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33604778?dopt=Abstract

Source: International Journal of Hematology - February 18, 2021 Category: Hematology Authors: Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M Tags: Int J Hematol Source Type: research

More News: Hematology | Japan Health | Lymphoma | Marketing | Study